Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Mereo Biopharma
UK biopharmaceutical company Mereo acquires and develops innovative therapeutics for rare and specialty diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Sumitovant
Sumitovant is a biopharmaceutical company focused on developing innovative medicines and therapies for patients.
Sector
Subsector
Keywords
Location
Cormorant Pharmaceuticals
Cormorant Pharmaceuticals develops therapeutics for cancer and rare diseases.
Sector
Subsector
Keywords
Location
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company that develops cancer therapies using a drug ratio technology platform.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds10
Number of Funding Rounds
Money Raised
Their latest funding was raised on 27.12.2022. Their latest round Post-IPO Debt
Runway Growth Capital
Runway Growth Capital extends financing and support to fast-growing companies.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
Co-Investors
Investors10
Number of lead investors
Number of investors
JAFCO
JAFCO Japan is a Tokyo-based venture capital, incubator, and private equity firm.
Sector
Subsector
Location
count Of Investments
count Of Exists
Biotech Healthcare Partners
Tokyo-based venture capital firm investing in biotech and healthcare in Asia Pacific.
Sector
Subsector
Keywords
count Of Investments
Runway Growth Capital
Runway Growth Capital extends financing and support to fast-growing companies.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
People
Founders1
Charles P. Theuer
Dr. Theuer has served as our President, Chief Executive Officer and a member of our board of directors since July 2006. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. At Pfizer, Dr. Theuer led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer’s previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology.
current job
organization founded
Charles P. Theuer
Employee Profiles17
Arlene Bolz
Administration and human resources manager
Activity
Recent News6
The graph reveals the ratio (%) of positive news articles in a chosen time range